INTRODUCTION AND OBJECTIVES:
There has been increasing awareness of the importance of three-dimensional culture of cancer cells. Tumor cells growing as multicellular spheroids (organoids) are believed to more closely mimic solid tumors in situ. Meanwhile, Wnt/ b-catenin pathway was reported to be upregulated in human bladder cancer specimens. However, no clear evidence has been reported that the pathway is directly involved in proliferation of bladder cancer cells. In this study, we assessed the involvement of Wnt/b-catenin pathway in proliferation of bladder cancer cells using organoid culture.
METHODS: Organoids from bladder cancer cell lines RT4 (luminal phenotype) and 5637 (basal phenotype) were generated by an aggregation method. A partial-digestion method was applied to prepare organoids directly from patient bladder cancer specimens. Wnt/b-catenin pathway was activated by using a small molecule CHIR99021 (GSK3 inhibitor, Wnt activator) and inhibited by siRNA against b-catenin. Activation of Wnt/b-catenin pathway was confirmed by upregulated AXIN2 mRNA expression and translocation of b-catenin into nucleus. Proliferation of cancer cells were evaluated by growth assay under microscope and ATP viability assay. Differentiation status of organoids over growth was characterized by qRT-PCR and western blot.
RESULTS: CHIR99021 inhibited proliferation of cell lines in conventional monolayer adherent culture, but promoted proliferation in three-dimensional organoid culture with activation of Wnt/b-catenin pathway. Enhanced proliferation of cancer cells with activation of Wnt/bcatenin pathway by CHIR99021 was also observed in patient-derived organoids. When b-catenin was knockdowned in cell lines, the growth of organoids was significantly suppressed. Cytokeratin 20, a terminal differentiation marker, was less expressed over CHIR99021-enhanced cell proliferation.
CONCLUSIONS: We showed for the first time that Wnt/b-catenin pathway was directly involved in proliferation of bladder cancer cells, suggesting that Wnt/b-catenin pathway may be a potential target for the treatment of a subset of bladder cancer. The above finding could not be observed when the same cells were grown in conventional twodimensional adherent cultures, providing a concrete example of why organoid culture is important for cancer research. Yuichiro Nakamura*, Yasuyoshi Miyata, Kyohei Araki, Takuji Yasuda, Tomohiro Matsuo, Kojiro Ohba, Bungo Furusato, Junya Fukuoka, Hideki Sakai, Nagasaki, Japan INTRODUCTION AND OBJECTIVES: Hepatocyte growth factor receptor/c-Met is a receptor tyrosine kinase that plays crucial roles in tumor growth, invasion, and metastasis in malignancies, including bladder cancer (BC). c-Met displays multiple functions via regulation of cyclooxygenase-2 (COX-2), hemeoxygenase-1 (HO-1) and programmed death ligand 1 (PD-L1) in various cancer types. However, the pathological significance of c-Met signaling system in BC is questionable. Here we investigate the pathological role of c-Met and phosphorylated c-Met in patients with BC.
METHODS: Expressions of c-Met and two tyrosine residues of c-Met (using phosphorylation site-specific antibodies for pY1234/ pY1235 and pY1349) were immunohistochemically examined and their correlation with COX-2, HO-1, and PD-L1 was investigated in 185 BC specimens. The relationship between expressions of c-Met and phosphorylated c-Met and clinicopathological features and expressions of COX-2, HO-1, and PD-L1 was analyzed.
RESULTS: Expressions of c-Met, pY1234/1235 c-Met, and pY1349 c-Met were associated with pT stage (P ¼ 0.013, P ¼ 0.002, and P < 0.001, respectively). In contrast, expressions of pY1234/1235 c-Met and pY1349 c-Met, but not c-Met, were associated with metastasis (P ¼ 0.003 and P ¼ 0.006, respectively). c-Met and pY1234/1235 c-Met correlated with PD-L1 (P < 0.001) and COX-2 (P ¼ 0.011), respectively, while a significant correlation was observed between pY1349 c-Met and COX-2, HO-1, and PD-L1 (P ¼ 0.006, P ¼ 0.002, and P < 0.001, respectively). The multi-variate analysis model including grade, pT stage, and metastasis demonstrated the independent correlation between c-Met and PD-L1 (odds ratio, [OR] ¼ 3.52, P < 0.001) as well as pY1349 c-Met and COX-2 (OR ¼ 2.35, P ¼ 0.015), HO-1 (OR ¼ 3.83, P ¼ 0.031), and PD-L1 (OR ¼ 3.33, P < 0.001). Among COX-2, HO-1, PD-L1, positive correlation was observed only between COX-2 and PD-L (P < 0.001). The multivariate analysis model including all pathological features and these molecules demonstrated that pY1349 c-Met and COX-2 were independently associated with PD-L1 expression (OR ¼ 5.54, P ¼ 0.002 and OR ¼ 4.33, P ¼ 0.037, respectively).
CONCLUSIONS: The expression of pY1349 c-Met was closely associated with malignant aggressiveness via regulation of COX-2, HO-1, and PD-L1. In addition, PD-L1 expression may be upregulated via the expression of COX-2 and c-Met by complex mechanisms. . 199, No. 4S, Supplement, Sunday, May 20, 2018 
